title: PDGFRA Antibody for Soft Tissue Sarcoma.
abstract: Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA. Olaratumab blocks ligand binding and thereby inhibits activation of PDGFRA kinase activity. Pre-clinically, this antibody inhibited PDGFRA-dependent tumor growth. In a randomized Phase II study, adding olaratumab to doxorubicin chemotherapy significantly improved overall survival, leading to FDA approval.
authors.affiliation: Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR 97239, USA.
authors.forename: Lillian R
authors.initials: LR
authors.lastname: Klug
authors.affiliation: Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, OR 97239, USA. Electronic address: heinrich@ohsu.edu.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Heinrich
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C000589393:olaratumab